Since hyperactivity of the protein kinase DYRK1A is linked to several neurodegenerative disorders, DYRK1A inhibitors have been suggested as potential therapeutics for Down syndrome and Alzheimer’s disease. The gene discussed is WEE1; the disease is early-onset autosomal dominant Alzheimer disease.